The University of Arizona is set to transform cognitive ageing research with the release of a comprehensive dataset in December 2025. This initiative, part of the...
Novo Nordisk announced on March 4, 2024, that its clinical trials for an oral version of the Alzheimer’s drug semaglutide did not succeed in slowing the...
CereCura Nanotherapeutics, a pre-clinical biotech startup based in Vancouver, has successfully secured $1.4 million CAD in seed funding to advance its innovative approach to treating neurological...
Families across Canada are expressing both hope and frustration as two promising drugs aimed at slowing the progression of Alzheimer’s disease remain unavailable in the country....
Patients and healthcare providers in Alberta are confronting a critical moment in the treatment of Alzheimer’s disease. Recent developments in dementia therapies could reshape the future...
